Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Core Viewpoint - Biodexa Pharmaceuticals PLC is convening a General Meeting to propose four resolutions aimed at restructuring its share capital and enhancing its ability to issue new shares [2][6]. Group 1: Resolutions Proposed - The first resolution proposes the subdivision of each issued ordinary share from £0.001 to one ordinary share of £0.00005 and 19 C deferred shares of £0.00005 each [2][5]. - The second resolution seeks authorization for the Directors to allot equity securities up to a nominal value of £476,954.10, expiring at the conclusion of the Annual General Meeting in 2028 [3]. - The third resolution empowers the Directors to allot equity securities for cash without the application of Section 561 of the Companies Act, also expiring at the conclusion of the Annual General Meeting in 2028 [4]. - The fourth resolution aims to approve and adopt new articles of association, replacing the existing ones [5]. Group 2: Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs [7]. - The company's lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancer [7][8][9][10]. - Biodexa utilizes proprietary drug delivery technologies to enhance the bio-delivery and bio-distribution of its medicines [11].